Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360

AIDS

Volumn 18, Issue 15, 2004, Pages 2019-2028

  Fikkert, Valery ^a   Hombrouck, Anneleen ^a   Van Remoortel, Barbara ^a   De Maeyer, Marc ^b   Pannecouque, Christophe ^a   De Clercq, Erik ^a   Debyser, Zeger ^a   Witvrouw, Myriam ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Antiviral drug resistance; HIV integrase inhibitors

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); INTEGRASE; INTEGRASE INHIBITOR; L 708906; NEVIRAPINE; SAQUINAVIR; UNCLASSIFIED DRUG; V 165; ZIDOVUDINE;

ARTICLE; CELL CULTURE; CELL STRAIN; COLORIMETRY; CONTROLLED STUDY; CROSS RESISTANCE; DNA BINDING; DRUG SENSITIVITY; ENZYME ACTIVE SITE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

ANTI-HIV AGENTS; CELLS, CULTURED; CLONE CELLS; DRUG RESISTANCE, VIRAL; FURANS; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; TRIAZOLES; VIRUS REPLICATION;

EID: 7744240084     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200410210-00006     Document Type: Article

References (28)

1. LaFemina RL, Schneider CL, Robbins HL, Callahan PL, LeGrow K, Roth E, et al. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol 1992; 66:7414-7419.
2. Sakai H, Kawamura M, Sakugari J, Sakugari S, Shibata R, Ishimoto A, et al. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol 1993; 67:1169-1174.
3. Debyser Z, Cherepanov P, Van Maele B, De Clercq E, Witvrouw M. In search of authentic inhibitors of HIV-1 integration. Antivir Chem Chemother 2002; 13:1-15.
4. Young SD. Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics. Curr Opin Drug Discov Devel 2001; 4:402-410.
5. Brown PO. Integration of retroviral DNA. Curr Topics Microbiol Immunol 1997; 157:19-47.
6. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J. Virol 1997; 71:5382-5390.
7. Chow SA, Vincent KA, Ellison V, Brown PO. Reversal of integration and DNA splicing mediated by integrase of HIV. Science 1992; 255:723-726.
8. Yoder KE, Bushman FD. Repair of gaps in retroviral DNA integration intermediates. J Virol 2000; 74:11191-11200.
9. Bushman FD, Craigie R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc Natl Acad Sci USA 1991; 88:1339-1343.
10. Sherman PA, Fyfe JA. Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc Natl Acad Sci USA 1990; 87:5119-5123.
11. Pommier Y, Neamati N. Inhibitors of human immunodeficiency virus integrase. Adv Virus Res 1999; 52:427-458.
12. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-650.
13. Pannecouque C, Pluymers W, Van Maele B, Tetz V, Cherepanov P, De Clercq E, et al. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol 2002; 12:1169-1177.
14. Pluymers W, Pais G, Pannecouque C, Fikkert V, Pommier Y, Burke Jr. TR, et al. Inhibition of HIV-1 integrase activity and HIV-1 replication by a series of diketo derivatives. Antimicrob Agents Chemother 2002; 46:3292-3297.
15. Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs 2003; 4:206-209.
16. Zhuang L, Wai JS, Embrey MW, Fisher TE, Egbertson MS, Payne LS, et al. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J Med Chem 2003; 13;46:453-456.
17. Young S and the HIV Integrase Discovery Team, Merck & Co. Inc. L-870, 810: a potent antiviral HIV integrase inhibitor with potential clinical utility. XIV International AIDS Conference, Barcelona, 2002 [abstract LbPeA9007].
18. Bridger GJ, Skerlj RT, Radmanabhan S, Martellucci SA, Henson GW, Struyf S, et al. Synthesis and structure-activity relationship of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effect of heteroaromatic linkers on the activity of bicyclams. J Med Chem 1995; 38:366-378.
19. Horwitz JP, Chua J, Noel M. Nucleosides. V. The monomesylates of 1-(2′-deoxy-β-D-lyxofuranosyl)thymidine. J Org Chem 1964; 29:2076-2078.
20. Miyoshi I, Taguchi H, Kobonishi I, Yoshimoto S, Ohtsuki Y, Shiraishi Y. Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogram 1982; 28:219-228.
21. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224:497-500.
22. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59:284-291.
23. Fikkert V, Van Maele B, Vercammen J, Hantson A, Van Remoortel B, Michiels M, et al. Development of resistance against diketo derivatives of human immunodeficiency virus-1 by progressive accumulation of integrase mutations. J Virol 2003;77:11459-11470.
24. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988; 20:309-321.
25. Wang JY, Ling H, Yang W, Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J 2001; 20:7333-7343.
26. Chen JC, Krucinski J, Miercke LJ, Finer-Moore JS, Tang AH, Leavitt AD, et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci USA 2000; 97:8233-8238.
27. Yoshinaga T, Sato A, Fujishita T, Fujiwara T. S-1360: in-vitro activity of a new HIV-1 integrase inhibitor in clinical development. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle 2002, [oral abstract 8].
28. Kulkosky J, Jones KS, Katz RA, Mack JP, Skalka AM. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol 1992; 12:2331-2338.